BRPI0518565A2 - composiÇÕes cardiovasculares - Google Patents

composiÇÕes cardiovasculares

Info

Publication number
BRPI0518565A2
BRPI0518565A2 BRPI0518565-3A BRPI0518565A BRPI0518565A2 BR PI0518565 A2 BRPI0518565 A2 BR PI0518565A2 BR PI0518565 A BRPI0518565 A BR PI0518565A BR PI0518565 A2 BRPI0518565 A2 BR PI0518565A2
Authority
BR
Brazil
Prior art keywords
compositions
cardiovascular
promote
health
maintain
Prior art date
Application number
BRPI0518565-3A
Other languages
English (en)
Inventor
Jonathan David Bortz
Mitchell I Kirschner
Marc S Hermelin
David S Hermelin
Original Assignee
Drugtech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drugtech Corp filed Critical Drugtech Corp
Publication of BRPI0518565A2 publication Critical patent/BRPI0518565A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

COMPOSIÇÕES CARDIOVASCULARES. A presente invenção refere-se a composições que promovem e/ou mantêm a saúde cardiovascular através do tratamento de uma ou mais doenças cardiovasculares. Também são fornecidos métodos para uso de composições que promovem e/ou mantêm a saúde cardiovascular através da prevenção, estabilização, reversão e/ou tratamento de doença arterial coronária e/ou doença cerebrovascular. Tais composições podem ser usadas independentemente para promover e/ou manter a saúde cardiovascular ou usadas em combinação com uma ou mais outras composições usadas no tratamento de vários outros estados de doença comuns ao envelhecimento e/ou a uma condição de deterioração de saúde.
BRPI0518565-3A 2004-12-22 2005-10-20 composiÇÕes cardiovasculares BRPI0518565A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/021,282 US20060135610A1 (en) 2004-12-22 2004-12-22 Cardiovascular compositions
PCT/US2005/038227 WO2006071342A2 (en) 2004-12-22 2005-10-20 Cardiovascular compositions

Publications (1)

Publication Number Publication Date
BRPI0518565A2 true BRPI0518565A2 (pt) 2008-11-25

Family

ID=36596911

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518565-3A BRPI0518565A2 (pt) 2004-12-22 2005-10-20 composiÇÕes cardiovasculares

Country Status (11)

Country Link
US (1) US20060135610A1 (pt)
EP (1) EP1838323A4 (pt)
JP (1) JP2008525441A (pt)
CN (1) CN101123969A (pt)
AR (1) AR052836A1 (pt)
AU (1) AU2005322584A1 (pt)
BR (1) BRPI0518565A2 (pt)
CA (1) CA2594212A1 (pt)
MX (1) MX2007007781A (pt)
PE (1) PE20060764A1 (pt)
WO (1) WO2006071342A2 (pt)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US7399755B2 (en) * 2005-02-17 2008-07-15 Premier Micronutrient Corporation Formulations comprising multiple dietary and endogenously made antioxidants and B-vitamins and use of same
US20090203778A1 (en) * 2005-05-04 2009-08-13 Morten Bryhn Fatty acid analogues, i.e. including dha derivatives for uses as a medicament
US20070299017A1 (en) * 2006-06-23 2007-12-27 Kanter Mitchell M Compositions for lowering blood serum cholesterol and use in foods, beverages, and health supplements
EP1882473A1 (en) * 2006-07-28 2008-01-30 Indena S.P.A. Use of anthocyanosides to prepare formulations for the treatment of mucositis induced by antitumoral drugs
US20080064702A1 (en) * 2006-09-08 2008-03-13 Charalambos Antoniades Use of folates for the prevention and treatment of vascular diseases
US7282225B1 (en) 2006-09-27 2007-10-16 Occular Technologies, Inc. Composition and methods for improving retinal health
RU2507193C2 (ru) * 2006-11-01 2014-02-20 Пронова Биофарма Норге А/С Альфа-замещенные омега-3 липиды, которые являются активаторами или модуляторами рецептора, активируемого пролифераторами пероксисом (ppar)
CN101535238A (zh) * 2006-11-01 2009-09-16 普罗诺瓦生物医药挪威公司 作为过氧化物酶体增生物激活受体(PPAR)的活化剂或调节剂的α-取代的ω-3脂质
JP2010508262A (ja) * 2006-11-01 2010-03-18 プロノヴァ バイオファーマ ノルゲ アーエス 組成物
JP5552314B2 (ja) * 2006-11-01 2014-07-16 プロノヴァ バイオファーマ ノルゲ アーエス 新規脂質化合物
GB2459809A (en) * 2007-02-22 2009-11-11 Children S Hospital And Res Ct Fatty acid formulations and methods of use thereof
JP5575651B2 (ja) * 2007-10-31 2014-08-20 プロノヴァ バイオファーマ ノルゲ アーエス 新規のｄｈａ誘導体およびその医薬品としての用途
US8318708B2 (en) * 2007-11-06 2012-11-27 Salk Institute For Biological Studies Use of vitamin D receptor agonists, ligands, and precursors to treat pancreatic fibrosis
EP2209377B8 (en) * 2007-11-06 2018-10-17 The Salk Institute For Biological Studies Use of vitamin d receptor agonists and precursors to treat fibrosis
US8586104B2 (en) * 2008-04-10 2013-11-19 U.S. Nutraceuticals, LLC Plant derived seed extract rich in essentially fatty acids derived from Salvia hispanica L. seed: composition of matter, manufacturing process and use
US8784904B2 (en) * 2008-04-10 2014-07-22 U.S. Nutraceuticals, LLC Plant derived seed extract rich in essential fatty acids derived from perilla seed: composition of matter, manufacturing process and use
WO2010015335A1 (en) * 2008-08-07 2010-02-11 Spa Societa' Prodotti Antibiotici S.P.A. Long-term treatment of symptomatic heart failure
EP3187182B1 (en) 2008-09-02 2021-03-03 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
WO2010064665A1 (ja) * 2008-12-01 2010-06-10 辻堂化学株式会社 治療剤
WO2010063652A1 (en) * 2008-12-04 2010-06-10 Sanofi-Aventis Methods and uses involving heme binding protein 1
MX2011008448A (es) 2009-02-10 2012-02-28 Amarin Pharma Inc Uso de ester etilico del acido eisosapentaenoico para tratar hipertrigliceridemia.
US20100239660A1 (en) * 2009-03-19 2010-09-23 Doughman Scott D Product and use of omega-3s matching human tissue ratios for treatment of inflammatory and other conditions
NO2424356T3 (pt) 2009-04-29 2018-01-20
EP3563842A1 (en) 2009-04-29 2019-11-06 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
ES2661217T3 (es) 2009-06-15 2018-03-28 Amarin Pharmaceuticals Ireland Limited Composiciones y métodos para reducir los triglicéridos sin aumentar los niveles de LDL-C en un sujeto en terapia simultánea con estatinas
WO2011038122A1 (en) 2009-09-23 2011-03-31 Amarin Corporation Plc Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
CA3066588C (en) * 2010-03-04 2022-03-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating and/or preventing cardiovascular disease
US8563267B2 (en) * 2010-07-22 2013-10-22 Asia-Pacific Beiotech Developing, Inc. Lycogen extract, composition thereof and method for the treatment using the same
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EP2646013A4 (en) 2010-11-29 2014-03-26 Amarin Pharma Inc COMPOSITION WITH LOW IMPACT EFFECT AND METHOD FOR THE TREATMENT AND / OR PREVENTION OF CARDIOVASCULAR DISEASES IN A PATIENT WITH FISH ALLERGY / SENSITIVITY
US10709680B2 (en) * 2011-07-18 2020-07-14 Physicians Recommended Nutriceuticals, Llc Methods for treating dry eye
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
JP6307442B2 (ja) 2012-01-06 2018-04-04 アマリン ファーマシューティカルス アイルランド リミテッド 対象の高感度（ｈｓ−ｃｒｐ）のレベルを低下させる組成物および方法
MA50258A1 (fr) 2012-06-29 2023-07-31 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'un événement cardiovasculaire chez un sujet soumis à un traitement par une statine
CN102901788B (zh) * 2012-08-31 2014-09-10 江苏省农业科学院 叶黄素二琥珀酸酯的测定方法
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
MX2015014701A (es) 2013-04-24 2016-08-08 Salk Inst For Biological Studi Circuito genomico del receptor de vitamina d/smad que regula la compuerta de la respuesta fibrotica.
EP3003486A4 (en) 2013-06-05 2017-03-08 Salk Institute for Biological Studies Vitamin d receptor agonists to treat diseases involving cxcl12 activity
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
ES2813383T3 (es) * 2013-12-19 2021-03-23 Tassos Georgiou Composición de ácidos grasos omega 3 para tratar enfermedades que implican daños en el sistema nervioso
CN106103678B (zh) 2014-03-17 2019-09-17 兴人生命科学株式会社 含有磷脂型α亚麻酸的组合物
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
CN104940933A (zh) * 2015-06-15 2015-09-30 青岛大学附属医院 一种用于预防治疗心血管疾病的药物
CA3000569A1 (en) * 2015-09-30 2017-04-06 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US11978543B2 (en) * 2016-12-14 2024-05-07 Astarte Medical Partners Inc. System and methods for developing and using a microbiome-based action component
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
WO2019023149A1 (en) 2017-07-24 2019-01-31 Salk Institute For Biological Studies USE OF BROMODOMAIN-CONTAINING PROTEIN-9 ANTAGONISTS IN ASSOCIATION WITH VITAMIN D RECEPTOR AGONISTS IN THE TREATMENT OF DIABETES
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
EP3700518A4 (en) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ireland Limited METHODS FOR REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN A SUBJECT
WO2020138556A1 (ko) * 2018-12-28 2020-07-02 경상대학교병원 혈관 확장 감소 억제용 의약 조성물
EP4326244A1 (en) 2021-04-21 2024-02-28 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3697559A (en) * 1971-02-25 1972-10-10 Wisconsin Alumni Res Found 1,25-dihydroxycholecalciferol
US4097602A (en) * 1974-11-29 1978-06-27 Silver Melvin J Method of inhibiting blood platelet aggregation
US4670285A (en) * 1982-08-06 1987-06-02 The University Of Toronto Innovations Foundation Infant formula
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US5059622A (en) * 1989-08-29 1991-10-22 Biosyn, Inc. Method for reducing blood pressure levels in hypertensive persons
US5405613A (en) * 1991-12-11 1995-04-11 Creative Nutrition Canada Corp. Vitamin/mineral composition
SE9200541D0 (sv) * 1992-02-24 1992-02-24 Kabi Pharmacia Ab New usee of omega-3-fatty acids
US5223285A (en) * 1992-03-31 1993-06-29 Abbott Laboratories Nutritional product for pulmonary patients
GB9404483D0 (en) * 1994-03-08 1994-04-20 Norsk Hydro As Refining marine oil compositions
MY118354A (en) * 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
AU6141498A (en) * 1997-02-04 1998-08-25 John V. Kosbab Compositions and methods for prevention and treatment of vascular degenerative diseases
EP0891719A1 (en) * 1997-07-14 1999-01-20 N.V. Nutricia Nutritional composition containing methionine
US5922704A (en) * 1997-12-24 1999-07-13 Feeling Fine Company Llc Optimal nutritional supplement for men
US6048846A (en) * 1998-02-26 2000-04-11 Cochran; Timothy M. Compositions used in human treatment
NO312973B1 (no) * 1999-02-17 2002-07-22 Norsk Hydro As Lipase-katalysert forestring av marine oljer
US6569857B1 (en) * 1999-05-03 2003-05-27 Drugtech Corporation Dietary supplement
NO310113B1 (no) * 1999-08-11 2001-05-21 Norsk Hydro As Fremgangsmåte for utvinning av flerumettede fettsyrer fra ureakomplekser
US6479545B1 (en) * 1999-09-30 2002-11-12 Drugtech Corporation Formulation for menopausal women
BR0001794A (pt) * 2000-05-15 2001-12-26 Laboratorios Biosintetica Ltda Aplicação de fitosteróides (e seus isÈmeros), ácidofólico, cianocobalamina e piridoxina em fibrasdietéticas (alimentares)
US6579544B1 (en) * 2000-05-31 2003-06-17 Nutriex, L.L.C. Method for supplementing the diet
GB0016045D0 (en) * 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
AU3651102A (en) * 2000-11-29 2002-06-11 Smithkline Beecham Corp Composition containing statins and calcium for improved cardiovascular health
EP1347745A4 (en) * 2000-11-29 2007-10-17 Smithkline Beecham DIET WITH CONJUGATED LINOLIC ACID AND CALCIUM FOR IMPROVED HEALTH
JP3533605B2 (ja) * 2001-12-06 2004-05-31 すこやか食品株式会社 血圧降下、心臓強化、動脈硬化防止、血管保護、抗疲労、運動機能向上、エネルギー代謝効率向上、抗酸化などの諸効果を有する栄養補助食品。
US6551629B1 (en) * 2002-07-03 2003-04-22 Vitacost.Com, Inc. Cardiovascular promotion and maintenance composition
US6649195B1 (en) * 2002-07-11 2003-11-18 Vitacost.Com, Inc. Eyesight enhanced maintenance composition
FR2869502B1 (fr) * 2004-04-28 2006-07-21 Cybelia Soc Par Actions Simpli Aliments pour poules pondeuses, procede d'alimentation et oeuf enrichi en elements essentiels

Also Published As

Publication number Publication date
CA2594212A1 (en) 2006-07-06
AR052836A1 (es) 2007-04-04
JP2008525441A (ja) 2008-07-17
PE20060764A1 (es) 2006-08-16
WO2006071342A3 (en) 2007-08-09
EP1838323A2 (en) 2007-10-03
AU2005322584A1 (en) 2006-07-06
EP1838323A4 (en) 2008-06-18
WO2006071342A2 (en) 2006-07-06
MX2007007781A (es) 2007-08-22
CN101123969A (zh) 2008-02-13
US20060135610A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
BRPI0518565A2 (pt) composiÇÕes cardiovasculares
BRPI0519265A2 (pt) composiÇÕes incluindo ferro
BRPI0612119A2 (pt) tratamento de distúrbio auto-imunes com uma neuroxotina
NO20064584L (no) Tetrahydropyridoindolderivater
ECSP074704A (es) Combinaciones de inhibidor(es) de la absorción de esterol con modificador(es) sanguíneos para tratar cuadros vasculares
NO20070049L (no) Pyrrolotriazinderivater anvendelig for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese
ATE521608T1 (de) Glucokinaseaktivatoren
CY1108342T1 (el) Ανοσορρυθμιστικοι ολιγοσακχαριτες
NO20060978L (no) Farmasoytiske blandingr for behandling av prematur ejakulasjon ved pulmonal inhalering
WO2006114774A3 (en) Pyrimidine derivatives and their use as p2y12 receptor antagonists
ECSP088503A (es) COMPUESTOS de LACTAMa y MÉTODOS DE USO DE LOS MISMOS
HUP0303917A2 (hu) Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
ATE381935T1 (de) Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen
BRPI0609393B8 (pt) usos de um composto 11-desóxi-prostaglandina
BRPI0618451A2 (pt) derivados de piridopirazina, seu uso, composição farmacêutica e estojo
CY1112790T1 (el) Χρηση μαγιας σεληνιου στην αντιμετωπιση της νοσου αλτσχαιμερ
EA200701995A1 (ru) Способы уменьшения кальцификации
WO2018042438A3 (en) Human blood-derived products having decreased fibrinolytic activity and uses thereof in hemostatic disorders
PL373465A1 (en) Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives
BR0111601A (pt) Método para o tratamento de doença cardiovascular
NO20041598L (no) Fremgangsmater for behandling eller profylakse av vaskulaer betennelse ved anvendelse av sterolabsorpsjonsinhibitor(er)
NO20074780L (no) Heterocyklylamidsubstituerte imidazoler
BR112022001341A2 (pt) Inibidores de enzima
WO2006012504A3 (en) Compounds and methods for treatment of thrombosis
BR112022018645A2 (pt) Composições e métodos para tratar ou prevenir doenças inflamatórias, incluindo diabetes mellitus tipo i e tipo ii e doenças da tireoide

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.